Download PDF
Semin Reprod Med 2014; 32(04): 245-252
DOI: 10.1055/s-0034-1375176
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Food and Drug Supplements to Improve Fertility Outcomes

Bulent Urman
1   Department of Obstetrics and Gynecology, American Hospital, Istanbul, Turkey
2   Department of Obstetrics and Gynecology, Koc University School of Medicine, Istanbul, Turkey
,
Ozgur Oktem
1   Department of Obstetrics and Gynecology, American Hospital, Istanbul, Turkey
2   Department of Obstetrics and Gynecology, Koc University School of Medicine, Istanbul, Turkey
› Author Affiliations
Further Information

Publication History

Publication Date:
11 June 2014 (online)

    Permissions and Reprints

Abstract

Food and drug supplements (FDS) are extensively used by infertile couples either to supplement medical infertility treatment and assisted conception or as a means to independently improve conception rates. The majority of FDS are composed of antioxidants that are used for male and female infertility. Their use, despite being biologically plausible, lacks scientific support due to limitations stemming from poorly designed small studies. FDS and for that matter complementary and alternative medicine (CAM) is plagued by fallacies that confuse or mislead the public and thus may prevent many patients from making the right therapeutic decisions regarding their infertility problem. We do concur that the absence of evidence is not the evidence of absence; however, one should be wary of the apparent benign effects of FDS and CAM. The current literature seems to suggest a beneficial effect of antioxidants on male infertility. There is, however, no FDS that has been proven beyond doubt to increase conception rates in female infertility. The additive value of CAM and FDS on the success of assisted conception is also not known. Well-designed randomized studies are urgently needed given the popularity and ever increasing consumption of these supplements by the infertile couples.

Keywords

food supplements - drug supplements - infertility - fertility - antioxidants - alternative medicine
 

  • References

  • 1 Dennehy CE. The use of herbs and dietary supplements in gynecology: an evidence-based review. J Midwifery Womens Health 2006; 51 (6) 402-409
    CrossrefPubMedGoogle Scholar
  • 2 Eisenberg DM, Davis RB, Ettner SL , et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998; 280 (18) 1569-1575
    CrossrefPubMedGoogle Scholar
  • 3 Zoorob RJ, Sidani M, Williams J, Grief SN. Women's health: selected topics. Prim Care 2010; 37 (2) 367-387
    CrossrefPubMedGoogle Scholar
  • 4 Foresta C, Bettella A, Garolla A, Ambrosini G, Ferlin A. Treatment of male idiopathic infertility with recombinant human follicle-stimulating hormone: a prospective, controlled, randomized clinical study. Fertil Steril 2005; 84 (3) 654-661
    CrossrefPubMedGoogle Scholar
  • 5 Selice R, Garolla A, Pengo M, Caretta N, Ferlin A, Foresta C. The response to FSH treatment in oligozoospermic men depends on FSH receptor gene polymorphisms. Int J Androl 2011; 34 (4) 306-312
    CrossrefPubMedGoogle Scholar
  • 6 Vandekerckhove P, Lilford R, Vail A, Hughes E. Clomiphene or tamoxifen for idiopathic oligo/asthenospermia. Cochrane Database Syst Rev 2000; (2) CD000151
    PubMedGoogle Scholar
  • 7 Raman JD, Schlegel PN. Aromatase inhibitors for male infertility. J Urol 2002; 167 (2, Pt 1) 624-629
    CrossrefPubMedGoogle Scholar
  • 8 Vandekerckhove P, Lilford R, Vail A, Hughes E. Androgens versus placebo or no treatment for idiopathic oligo/asthenospermia. Cochrane Database Syst Rev 2000; (2) CD000150
    PubMedGoogle Scholar
  • 9 Ross C, Morriss A, Khairy M , et al. A systematic review of the effect of oral antioxidants on male infertility. Reprod Biomed Online 2010; 20 (6) 711-723
    CrossrefPubMedGoogle Scholar
  • 10 Tremellen K, Miari G, Froiland D, Thompson J. A randomised control trial examining the effect of an antioxidant (Menevit) on pregnancy outcome during IVF-ICSI treatment. Aust N Z J Obstet Gynaecol 2007; 47 (3) 216-221
    CrossrefPubMedGoogle Scholar
  • 11 Zini A, Al-Hathal N. Antioxidant therapy in male infertility: fact or fiction?. Asian J Androl 2011; 13 (3) 374-381
    CrossrefPubMedGoogle Scholar
  • 12 Ramasamy R, Stahl PJ, Schlegel PN. Medical therapy for spermatogenic failure. Asian J Androl 2012; 14 (1) 57-60
    CrossrefPubMedGoogle Scholar
  • 13 Zini A, San Gabriel M, Baazeem A. Antioxidants and sperm DNA damage: a clinical perspective. J Assist Reprod Genet 2009; 26 (8) 427-432
    CrossrefPubMedGoogle Scholar
  • 14 Comhaire F, Decleer W. Quantifying the effectiveness and cost-efficiency of food supplementation with antioxidants for male infertility. Reprod Biomed Online 2011; 23 (3) 361-362
    CrossrefPubMedGoogle Scholar
  • 15 Allison JL, Schust DJ. Recurrent first trimester pregnancy loss: revised definitions and novel causes. Curr Opin Endocrinol Diabetes Obes 2009; 16 (6) 446-450
    CrossrefPubMedGoogle Scholar
  • 16 Gil-Villa AM, Cardona-Maya W, Agarwal A, Sharma R, Cadavid A. Role of male factor in early recurrent embryo loss: do antioxidants have any effect?. Fertil Steril 2009; 92 (2) 565-571
    CrossrefPubMedGoogle Scholar
  • 17 Agarwal A, Gupta S, Sharma RK. Role of oxidative stress in female reproduction. Reprod Biol Endocrinol 2005; 3: 28
    CrossrefPubMedGoogle Scholar
  • 18 Lloyd KB, Hornsby LB. Complementary and alternative medications for women's health issues. Nutr Clin Pract 2009; 24 (5) 589-608
    CrossrefPubMedGoogle Scholar
  • 19 Suzuki T, Sugino N, Fukaya T , et al. Superoxide dismutase in normal cycling human ovaries: immunohistochemical localization and characterization. Fertil Steril 1999; 72 (4) 720-726
    CrossrefPubMedGoogle Scholar
  • 20 Jones DP. Radical-free biology of oxidative stress. Am J Physiol Cell Physiol 2008; 295 (4) C849-C868
    CrossrefPubMedGoogle Scholar
  • 21 Shkolnik K, Tadmor A, Ben-Dor S, Nevo N, Galiani D, Dekel N. Reactive oxygen species are indispensable in ovulation. Proc Natl Acad Sci U S A 2011; 108 (4) 1462-1467
    CrossrefPubMedGoogle Scholar
  • 22 Park JI, Jeon HJ, Jung NK , et al. Periovulatory expression of hydrogen peroxide-induced sulfiredoxin and peroxiredoxin 2 in the rat ovary: gonadotropin regulation and potential modification. Endocrinology 2012; 153 (11) 5512-5521
    CrossrefPubMedGoogle Scholar
  • 23 Oyawoye OA, Abdel-Gadir A, Garner A, Leonard AJ, Perrett C, Hardiman P. The interaction between follicular fluid total antioxidant capacity, infertility and early reproductive outcomes during in vitro fertilization. Redox Rep 2009; 14 (5) 205-213
    CrossrefPubMedGoogle Scholar
  • 24 Henmi H, Endo T, Kitajima Y, Manase K, Hata H, Kudo R. Effects of ascorbic acid supplementation on serum progesterone levels in patients with a luteal phase defect. Fertil Steril 2003; 80 (2) 459-461
    CrossrefPubMedGoogle Scholar
  • 25 Prieto L, Quesada JF, Cambero O , et al. Analysis of follicular fluid and serum markers of oxidative stress in women with infertility related to endometriosis. Fertil Steril 2012; 98 (1) 126-130
    CrossrefPubMedGoogle Scholar
  • 26 Singh AK, Chattopadhyay R, Chakravarty B, Chaudhury K. Markers of oxidative stress in follicular fluid of women with endometriosis and tubal infertility undergoing IVF. Reprod Toxicol 2013; 42: 116-124
    CrossrefPubMedGoogle Scholar
  • 27 Mier-Cabrera J, Aburto-Soto T, Burrola-Méndez S , et al. Women with endometriosis improved their peripheral antioxidant markers after the application of a high antioxidant diet. Reprod Biol Endocrinol 2009; 7: 54
    CrossrefPubMedGoogle Scholar
  • 28 Griesinger G, Franke K, Kinast C , et al. Ascorbic acid supplement during luteal phase in IVF. J Assist Reprod Genet 2002; 19 (4) 164-168
    CrossrefPubMedGoogle Scholar
  • 29 Paszkowski T, Traub AI, Robinson SY, McMaster D. Selenium dependent glutathione peroxidase activity in human follicular fluid. Clin Chim Acta 1995; 236 (2) 173-180
    Google Scholar
  • 30 Özkaya MO, Nazıroğlu M, Barak C, Berkkanoglu M. Effects of multivitamin/mineral supplementation on trace element levels in serum and follicular fluid of women undergoing in vitro fertilization (IVF). Biol Trace Elem Res 2011; 139 (1) 1-9
    CrossrefPubMedGoogle Scholar
  • 31 Edassery SL, Shatavi SV, Kunkel JP , et al. Autoantigens in ovarian autoimmunity associated with unexplained infertility and premature ovarian failure. Fertil Steril 2010; 94 (7) 2636-2641
    Google Scholar
  • 32 Seko LM, Moroni RM, Leitao VM , et al. Melatonin supplementation during controlled ovarian stimulation for women undergoing assisted reproductive technology: systematic review and meta-analysis of randomized controlled trials. Fertil Steril 2014; 101 (1) 154 , e4
    CrossrefPubMedGoogle Scholar
  • 33 Bergmann J, Luft B, Boehmann S, Runnebaum B, Gerhard I. [The efficacy of the complex medication Phyto-Hypophyson L in female, hormone-related sterility. A randomized, placebo-controlled clinical double-blind study]. Forsch Komplementarmed Klass Naturheilkd 2000; 7 (4) 190-199
    CrossrefPubMedGoogle Scholar
  • 34 Roemheld-Hamm B. Chasteberry. Am Fam Physician 2005; 72 (5) 821-824
    PubMedGoogle Scholar
  • 35 Westphal LM, Polan ML, Trant AS, Mooney SB. A nutritional supplement for improving fertility in women: a pilot study. J Reprod Med 2004; 49 (4) 289-293
    PubMedGoogle Scholar
  • 36 Westphal LM, Polan ML, Trant AS. Double-blind, placebo-controlled study of Fertilityblend: a nutritional supplement for improving fertility in women. Clin Exp Obstet Gynecol 2006; 33 (4) 205-208
    PubMedGoogle Scholar
  • 37 Showell MG, Brown J, Clarke J, Hart RJ. Antioxidants for female subfertility. Cochrane Database Syst Rev 2013; 8: CD007807
    PubMedGoogle Scholar
  • 38 Luk J, Torrealday S, Neal Perry G, Pal L. Relevance of vitamin D in reproduction. Hum Reprod 2012; 27 (10) 3015-3027
    CrossrefPubMedGoogle Scholar
  • 39 Ott J, Wattar L, Kurz C , et al. Parameters for calcium metabolism in women with polycystic ovary syndrome who undergo clomiphene citrate stimulation: a prospective cohort study. Eur J Endocrinol 2012; 166 (5) 897-902
    CrossrefPubMedGoogle Scholar
  • 40 Ozkan S, Jindal S, Greenseid K , et al. Replete vitamin D stores predict reproductive success following in vitro fertilization. Fertil Steril 2010; 94 (4) 1314-1319
    CrossrefPubMedGoogle Scholar
  • 41 Aleyasin A, Aghahoseini M, Mokhtar S, Fallahi P. Anti-mullerian hormone as a predictive factor in assisted reproductive technique of polycystic ovary syndrome patients. Acta Med Iran 2011; 49 (11) 715-720
    PubMedGoogle Scholar
  • 42 Anifandis GM, Dafopoulos K, Messini CI , et al. Prognostic value of follicular fluid 25-OH vitamin D and glucose levels in the IVF outcome. Reprod Biol Endocrinol 2010; 8: 91
    CrossrefPubMedGoogle Scholar
  • 43 Ried K, Stuart K. Efficacy of traditional Chinese herbal medicine in the management of female infertility: a systematic review. Complement Ther Med 2011; 19 (6) 319-331
    CrossrefPubMedGoogle Scholar
  • 44 Gleicher N, Barad DH. Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reprod Biol Endocrinol 2011; 9: 67
    CrossrefPubMedGoogle Scholar
  • 45 Urman B, Yakin K. DHEA for poor responders: can treatment be justified in the absence of evidence?. Reprod Biomed Online 2012; 25 (2) 103-107
    CrossrefPubMedGoogle Scholar
  • 46 Urman B, Yakin K. Does dehydroepiandrosterone have any benefit in fertility treatment?. Curr Opin Obstet Gynecol 2012; 24 (3) 132-135
    CrossrefPubMedGoogle Scholar
  • 47 Yakin K, Urman B. DHEA as a miracle drug in the treatment of poor responders; hype or hope?. Hum Reprod 2011; 26 (8) 1941-1944
    CrossrefPubMedGoogle Scholar
  • 48 Thompson RD, Carlson M, Thompson RD, Carlson M. Liquid chromatographic determination of dehydroepiandrosterone (DHEA) in dietary supplement products. J AOAC Int 2000; 83 (4) 847-857
    PubMedGoogle Scholar
  • 49 Barad DH, Weghofer A, Gleicher N. Dehydroepiandrosterone treatment of ovarian failure. Fertil Steril 2009; 91 (5) e14 , author reply e15
    CrossrefPubMedGoogle Scholar
  • 50 Gleicher N, Weghofer A, Barad DH. Improvement in diminished ovarian reserve after dehydroepiandrosterone supplementation. Reprod Biomed Online 2010; 21 (3) 360-365
    CrossrefPubMedGoogle Scholar
  • 51 Wiser A, Gonen O, Ghetler Y, Shavit T, Berkovitz A, Shulman A. Addition of dehydroepiandrosterone (DHEA) for poor-responder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study. Hum Reprod 2010; 25 (10) 2496-2500
    CrossrefPubMedGoogle Scholar
  • 52 Kolibianakis EM, Venetis CA, Tarlatzis BC. DHEA administration in poor responders. Hum Reprod 2011; 26 (3) 730-731 , author reply 731
    CrossrefPubMedGoogle Scholar
  • 53 Kara M, Aydin T, Aran T , et al. Does dehydroepiandrosterone supplementation really affect IVF-ICSI outcome in women with poor ovarian reserve?. Eur J Obstet Gynecol Reprod Biol 2014; 173: 63-65
    CrossrefPubMedGoogle Scholar
  • 54 Raja-Khan N, Stener-Victorin E, Wu X, Legro RS. The physiological basis of complementary and alternative medicines for polycystic ovary syndrome. Am J Physiol Endocrinol Metab 2011; 301 (1) E1-E10
    CrossrefPubMedGoogle Scholar